Needham & Co. analyst Mike Matson upgraded Haemonetics Corporation (NYSE:HAE) from Hold to Buy with a price target of $112.
The analyst says that Haemonetics has reaffirmed its “high-20%” FY26 operating margin goal. To reach this, the company must improve by approximately 600 basis points from its FY24 margin of 21.1%, writes the analyst.
While the analyst earlier doubted the company’s ability to reach this target, the product mix analysis has bolstered their confidence.
The analyst has identified two key factors influencing the company’s gross margin, which includes ...Full story available on Benzinga.com
Related tickers: HAE, XHE, NBSM.
Read Full Article
